Jacobio to present pan-KRAS inhibitor data at AACR-NCI-EORTC 2025

Jacobio Pharmaceuticals Group will present preclinical data for its pan-KRAS inhibitor, JAB-23E73, at the AACR-NCI-EORTC 2025 International Conference on Molecular Targets and Cancer Therapeutics. The presentation, titled "Preclinical Investigation of Orally Bioavailable, Potent Pan-KRAS (ON/OFF) Inhibitor JAB-23E73," will be delivered through an abstract and poster session. The conference is scheduled from October 22 to October 26, 2025, in Boston, United States.

The abstract will be available via the conference app starting at 12 p.m. ET on Wednesday, October 22, 2025, and as a supplement in the AACR journal, Molecular Cancer Therapeutics. The JAB-23E73 poster presentation is slated for October 23, 2025, from 12:30 p.m. to 4:00 p.m. ET. JAB-23E73 is described as a highly potent, orally bioavailable pan-KRAS (ON/OFF) inhibitor, demonstrating high selectivity and sparing HRAS and NRAS inhibition.

Preclinical data indicate superior antitumor activity across various cancer types with KRAS driver mutations or amplification. JAB-23E73 induced tumor regression in KRAS-driven mouse models without significant body weight change, suggesting good tolerability. Phase I clinical trials for JAB-23E73 are ongoing in China (NCT06959615) and the United States (NCT06973564) for patients with advanced solid tumors harboring KRAS gene alterations.